CVS Announces Plans To Sell Generic Version Of EpiPen Amid Outcry Over Prices
The move also comes amid scrutiny over the role of pharmacy benefit managers in the controversy over EpiPen.
CVS Targets EpiPen With Cheaper, Generic Version
CVS Health said Thursday that it would sell a generic version of an EpiPen competitor for a lower list price in a bid to tap into a groundswell of public resentment over skyrocketing drug costs, including fresh attacks by President-elect Donald Trump. (Bomey, 1/12)
In other pharmaceutical news —
The Wall Street Journal:
Shire To Pay $350 Million To Settle Dermagraft Kickback Allegations
Shire PLC will pay $350 million to settle allegations a regenerative drugmaker it bought in 2011 used kickbacks to promote its core skin substitute product. New York Attorney General Eric Schneiderman’s office on Wednesday said an agreement was reached with New York, 37 other states and the District of Columbia to settle allegations that Shire and Advanced BioHealing illegally promoted Dermagraft, a bioengineered human skin substitute made from cells derived from newborn foreskin tissue for treating diabetic foot ulcers. (Steele, 1/11)